As part of its broader vision to evolve into a fully integrated pharmaceutical solutions provider, the company has laid critical groundwork over the next year focusing on international expansion, R&D enhancement, and operational transformation.
A key step in this strategy was the earlier incorporation of REMLIFE GLOBAL PTE. LTD. in Singapore, a wholly owned subsidiary that now functions as Remedium’s global commercial and capital markets interface. The move has enabled the company to tap into global investor ecosystems, streamline international operations and deepen its reach across key markets.
Aligned with this vision, Remedium had secured a ₹182.7 crore (USD 21 Million) multi-year export contract in February 2025 with a leading pharmaceutical distributor. This outcome highlights the company’s efforts to build a reliable, quality-driven, and scalable CDMO platform. The contract underscores Remedium’s growing global credibility and its transition from a trading-led model to a full-spectrum pharmaceutical solutions provider focused on compliance, quality, and innovation.
The robust participation in the recently concluded Rights Issue reflects strong investor confidence in the company’s fundamentals and future potential. The capital is being directed toward high-priority areas, including R&D upgrades, CDMO infrastructure, and expansion into regulated and semi-regulated international markets.
Remedium has invested significantly in enhancing its quality control and testing infrastructure, enabling improved product development and raw material validation—especially for its CDMO clients. While these upgrades do not immediately expand manufacturing capacity, they elevate formulation and compliance capabilities significantly.
Further advancing its sustainability agenda, Remlife Global PTE Ltd has partnered with Jia Yu Lifesciences PTE Ltd, a green chemistry platform focused on replacing animal-origin raw materials with scalable, sustainable bioprocesses.
“The incorporation of Remlife Global PTE Ltd in Singapore marked a pivotal milestone in our global strategy, enabling us to engage with international partners, raise capital more efficiently, and build long-term traction in high-opportunity markets. Our partnership with Jia Yu Lifesciences PTE Ltd further strengthens our innovation-led sustainability efforts. The strong response to our rights issue reaffirms investor belief in our vision. We remain focused on building a future-ready pharmaceutical platform that is globally integrated, compliant, and impact-driven,”—Adarsh Munjal, Whole Time Director, Remedium Lifecare Ltd.
With a growing global order book, diversified sourcing from India, Eastern Europe, and Southeast Asia, and built-in inventory buffers, Remedium is well-positioned to manage geopolitical risks while delivering high-value pharmaceutical products.
As the global pharma landscape becomes increasingly competitive and compliance-driven, Remedium is positioning itself through complex pharma offerings, regulatory-first strategies, cost-efficient CDMO services, and a strong sustainability focus—charting a long-term path toward becoming a differentiated and trusted global pharma partner.